MoonLake Immunotherapeutics Buoyed by 77% EULAR Response and $45 Price Target
MLTX•H.C. Wainwright reiterated its Buy rating with a $45 price target on MoonLake Immunotherapeutics, implying 150% upside. EULAR data showed Sonelokimab achieved 77% symptom improvement in axial spondyloarthritis within four weeks and over 50% partial remission by Week 12, and MoonLake cleared its final FDA pre-BLA meeting for hidradenitis suppurativa.
1. Analyst Rating and Price Target
H.C. Wainwright reiterated its Buy rating on MoonLake Immunotherapeutics and maintained a $45 price target, reflecting a 150% upside from the current share price. This reaffirmation underscores confidence in the commercial potential of Sonelokimab across key indications.
2. EULAR Conference Clinical Data
At the EULAR conference in London, Sonelokimab delivered rapid and deep responses in an open-label axial spondyloarthritis study. Seventy-seven percent of patients reported symptom improvement within four weeks, and over 50% reached partial remission by Week 12, highlighting strong efficacy signals.
3. FDA Pre-BLA Meeting Outcome
MoonLake completed its final FDA pre-Biologics License Application meeting for Sonelokimab in hidradenitis suppurativa, with regulators agreeing on submission plans, label strategy, adolescent inclusion and safety data requirements. No remaining regulatory gaps were identified, supporting a planned BLA submission by September.
4. Stock Reaction and Upcoming Catalysts
Shares of MoonLake rose about 1% in after-hours trading on the positive clinical readout and regulatory progress. Investors will monitor the September BLA submission, potential Priority Review designation by November and additional Sonelokimab data expected later this year.
